<title>Materials and methods</title> <title>Study design and patients</title> <p>This single-centre, open-label, non-randomised phase I/II study was conducted at the Christie Hospital (Manchester, UK) on patients with histologically confirmed, metastatic adenocarcinoma of the colon or rectum, with inoperable, measurable metastatic disease. Inclusion and exclusion criteria have been described previously (##REF##17213824##Sheikh et al, 2007##). In brief, patients were aged ⩾18 years, had no prior chemotherapy for metastatic disease and a World Health Organization performance status of 0–2. All patients had adequate organ and haematological function.</p> <p>The trial was conducted with full approval of the local ethical committee, according to accepted standards of good clinical practice, and in agreement with the latest version of the Declaration of Helsinki. All patients provided written informed consent.</p> <title>Treatment</title> <p>In the phase I study, patients received irinotecan 180 mg m<sup>−2</sup> as a 90 min infusion on day 1 of the 28-day cycle, oxaliplatin 85–100 mg m<sup>−2</sup> as a 2 h infusion on day 15 and UFT capsules 200–300 mg m<sup>−2</sup> d<sup>−1</sup> taken orally with LV 90 mg d<sup>−1</sup> in three divided doses on days 1–21. The MTD was irinotecan 180 mg m<sup>−2</sup>, oxaliplatin 100 mg m<sup>−2</sup> and UFT 250 mg m<sup>−2</sup> plus LV 90 mg. Prophylactic antiemetics (dexamethasone 8 mg and ondansetron 8 mg) were administered intravenously with the irinotecan and oxaliplatin infusions and thereafter orally for 48 h.</p> <p>Chemotherapy was administered for at least 8 weeks (two cycles) before radiological reassessment, unless a criterion for study discontinuation was met. Patients remained on treatment until clinical or radiological progression, the occurrence of unacceptable or cumulative toxicity or withdrawal was requested by the patient or investigator. Treatment was continued for a further 2 months in patients with signs of clinical benefit (stable disease or complete or partial response) up to 6 months. Selected patients could continue treatment for longer than 6 months at the investigator's discretion, and could receive further treatment with the SCOUT regimen or another treatment of the investigator's choice. Re-treatment with SCOUT was only allowed in patients who had not progressed during the initial treatment period.</p> <title>Dose reductions and delays</title> <p>Chemotherapy was delayed by 1 week in patients with neutropaenia grade ⩾2 or platelets &lt;100 × 10<sup>9</sup> l<sup>−1</sup> (&lt;75 × 10<sup>9</sup> l<sup>−1</sup> for oxaliplatin). If there was more than one delay or if a delay lasted ⩾2 weeks, doses of irinotecan and oxaliplatin were reduced by 20% and the daily UFT dose was reduced by one capsule (100 mg). Treatment continued at the lower dose for subsequent cycles unless further toxicity occurred. If a further delay for myelotoxicity occurred, 50% reduction was made to the original irinotecan and oxaliplatin doses. Withdrawal of the patient from the study was considered if their performance status had deteriorated.</p> <p>Delayed diarrhoea was treated early and aggressively with loperamide, with the addition of oral ciprofloxacin if it persisted for &gt;24 h. However, after grade 3/4 diarrhoea, treatment was delayed until complete recovery, and then resumed at 80% of the irinotecan dose and with the UFT daily dose reduced by one capsule. If diarrhoea of any grade had not resolved by the next cycle, treatment was delayed by 1 week. If further grade ⩾3 diarrhoea occurred, irinotecan was reduced to 50% of the original dose and the daily UFT dose was reduced by two capsules. Oxaliplatin was omitted for grade ⩾3 paraesthesia of hands or feet and dysaesthesia in the throat. Any significant deterioration in liver or renal function was investigated by ultrasound examination to rule out reversible biliary or renal outflow obstruction.</p> <title>Response and toxicity evaluation</title> <p>Patients were assessed clinically every 14 days and a full blood count and biochemistry profile performed. Serum tumour carcinoembryonic antigen (CEA) measurements were performed monthly if raised at baseline. Toxicities were recorded at 2-weekly visits according to the National Cancer Institute Common Toxicity Criteria (version 2) and the dose-limiting toxicities at 1 month, that is, diarrhoea, lethargy and vomiting, used to decide the dose escalation schedule during the phase I study, as reported previously (##REF##17213824##Sheikh et al, 2007##).</p> <p>Radiological assessment by CT scan was performed after two cycles using the Response Evaluation Criteria in Solid Tumors (RECIST) (##REF##10655437##Therasse et al, 2000##). All scans were performed by a dedicated gastrointestinal radiologist who provided measurements of marker lesions. From these measurements, response was confirmed by two research fellows. In cases of disagreement, scans were reviewed by the principal investigator. Only patients receiving two full 28-day cycles were assessable for the primary endpoint, that is, the objective response rate (ORR), defined as the number of patients achieving a partial or complete response at 8 weeks.</p>
<title>Results</title> <title>Patient characteristics</title> <p>Overall, 45 patients were treated, 29 of whom received the MTD. Patient demographics and clinical characteristics are shown in ##TAB##1##Table 2##. In total, seven patients did not receive two cycles of SCOUT and were not evaluable for response assessment; four of these patients were in the MTD group. The evaluable population therefore comprised 38 patients in total and 25 patients treated at the MTD. Overall, five patients were not assessable for time to progression (TTP), two of whom were treated at the MTD (three patients died before completing an assessment scan after two cycles and two withdrew for psycho-social reasons). All patients were assessable for toxicity and OS. A majority of patients had multiple lesions; only six patients had disease confined to the liver.</p> <title>Response to treatment</title> <p>Response to treatment is shown in ##TAB##2##Table 3##.</p> <p>An ORR of 68% (95% CI: 46–85%) and a disease-control rate of 100% (95% CI: 86–100%) were observed in the 25 evaluable patients who received the MTD. Median OS was 19.6 months in 29 assessable patients (95% CI: 15.5–27.2) (##FIG##0##Figure 1A##) and median TTP was 8.5 months in 27 assessable patients (95% CI: 7.6–11.1) (##FIG##0##Figure 1B##). One-year survival was 72.4% (95% CI: 52.3–85.1%) and 2-year survival was 37.2% (95% CI: 13.2–61.8%).</p> <p>The ORR in the 38 evaluable patients in the phase I/II study was 63% (95% CI: 46–78%), with a disease-control rate of 89% (95% CI: 75–97%). After a median follow-up of 14.9 months, median OS was 16.8 months (95% CI: 9.6–25.3) in 45 evaluable patients (##FIG##0##Figure 1C##) and median TTP was 8.7 months (95% CI: 7.9–10.4) in 40 evaluable patients (##FIG##0##Figure 1D##). One-year survival was 62.2% (95% CI: 46.4–74.6%) and 2-year survival was 38.7% (95% CI: 21.6–55.5%).</p> <p>Liver resections were performed on three patients. One patient with a partial response after four cycles underwent an R0 resection, one patient who had stable disease after three cycles had an R1 resection and one patient who had 5 cycles and achieved a partial response had an R1 resection. Another patient, who underwent a total of 11 treatment cycles and achieved a partial response on a re-challenge with SCOUT is being assessed for liver resection.</p> <title>Tolerability</title> <p>Tolerability data for the phase I cohort are detailed in our earlier publication. In the MTD group, 138 UFT courses were prescribed to the 29 patients, 16 of which were reduced by 1 capsule daily and 8 of which were reduced by 2 capsules daily; 21 patients (72%) received UFT without a dose reduction, 13 of whom (45%) received all 6 UFT cycles at full dose. A total of 139 doses of irinotecan therapy were administered, 17 doses were reduced by 20% and 3 by 50%; 132 doses of oxaliplatin were administered, 9 were reduced by 20% and 5 by 50%. The median dose intensity was 89% for both irinotecan and oxaliplatin after two cycles; 92% and 91% for irinotecan and oxaliplatin, respectively, after four cycles; and 95% and 92% for irinotecan and oxaliplatin, respectively, after six cycles.</p> <p>SCOUT was well tolerated at the MTD, as shown in ##TAB##3##Table 4##. One patient developed grade 3 neutropaenia and another had grade 3 leucopaenia. One patient with a history of hypertension, atrial fibrillation and type II diabetes had a grade 4 cardiac event and died following a myocardial infarction before cycle four. Alopecia and neurotoxicity were minimal: three patients (10%) had grade 2 alopecia and three (10%) had grade 2/3 neurotoxicity. Hand–foot syndrome grade &gt;1 was not observed.</p> <title>Second-line therapy</title> <p>After failure of first-line therapy, 24 out of the 29 patients (83%) treated at the MTD were considered for second-line treatment; 3 patients had not progressed at the time of the analysis and a further 2 patients were excluded as they were not assessable for progression, as described above. Six patients (25%) were deemed unfit to receive second-line therapy. Eighteen patients received second-line therapy (##TAB##4##Table 5##). Nine patients (38%) resumed SCOUT, eight of whom were assessable for response: one patient had a complete response (13%); three had partial responses (38%); one had stable disease (13%) and three had progressive disease (38%). Therefore, the ORR to re-treatment with SCOUT in the MTD group was 50% and the disease control rate was 63%. Twelve patients received other second-line regimens, including capecitabine-, irinotecan- and oxaliplatin-based regimens, as detailed in ##TAB##4##Table 5##.</p> <p>If patients treated at all doses are considered, 36 out of the 45 patients (80%) were considered for second-line therapy, 12 (33%) of whom were deemed unfit for further chemotherapy. Twelve (50%) of the 24 patients who received second-line chemotherapy resumed SCOUT. Two of the additional three patients from the phase I study who resumed SCOUT responded to the re-challenge with stable disease, and one had progressive disease. Therefore, the ORR to re-treatment with SCOUT chemotherapy in all patients was 36% and the disease control rate was 64%.</p> <p>Nine out of the 12 patients (75%) who received second-line SCOUT went on to receive a third-line chemotherapy regimen, as shown in ##TAB##4##Table 5##.</p> <p>Out of the remaining 12 patients who received second-line therapies other than SCOUT, 3 (25%) went on to receive a third-line agent (mitomycin C/capecitabine: <italic>n</italic>=2; XELOX: <italic>n</italic>=1).</p>
<title>Discussion</title> <p>Recent studies have demonstrated that triple-drug regimens can improve survival and response in patients with mCRC. Many of these regimens, however, can be associated with excessive toxicities. Alternating therapy, in which only two out of the three drugs are administered at one time, provides a means of delivering three effective drugs while minimising toxicity. The results from the present study confirm that alternating irinotecan and oxaliplatin during treatment with UFT with LV allows patients to receive an effective triple-drug regimen without the excessive haematological toxicities often observed with such treatments.</p> <p>The combination of UFT with LV plus irinotecan and oxaliplatin was highly effective, with excellent ORRs that were consistent with the phase I study results and better than those reported for UFT with LV plus irinotecan (##REF##15868381##Mendez et al, 2005##; ##REF##17637682##Delord et al, 2007##; ##REF##17245343##Bajetta et al, 2007a##) or UFT with LV plus oxaliplatin (##REF##15505621##Feliu et al, 2004##; ##REF##16118508##Rosati et al, 2005##; ##REF##16404362##Bennouna et al, 2006##; ##REF##17245343##Bajetta et al, 2007a##), providing further support for the up-front treatment approach. Particularly notable was the fact that all patients treated at the MTD benefited from therapy, with partial responses in 68% patients and stable disease in 32%. The OS of 19.6 months seen in patients treated at the MTD was comparable with results obtained for other triplet regimens (##TAB##0##Table 1##).</p> <p>Alternating oxaliplatin and irinotecan every 2 weeks allowed relatively high doses of both agents to be used without significant toxicities. Alopecia and neurotoxicity, which are commonly observed in patients treated with irinotecan and oxaliplatin, were minimal in our patients. Grade 2 alopecia was observed in three patients (7%) and only one patient had grade 3 neuropathy. Another feature of this study was the very low incidence of grade 3/4 haematological toxicities. This is likely to be a result of the alternating schedule, in which a 4-week gap between each dose of irinotecan and each dose of oxaliplatin allowed patients to recover from oxaliplatin- and irinotecan-induced toxicities before each drug was administered again. Indeed, at the MTD, only one patient had grade 3 neuropathy. Grade 3/4 toxicities were mainly gastrointestinal, with grade 3 diarrhoea in 10% patients. The single grade 4 adverse event observed at the MTD was an unrelated cardiac event in a patient with a history of hypertension, atrial fibrillation and type II diabetes. Hand–foot syndrome, a disturbing and disabling condition that can impact the quality of life of affected patients (##REF##15471200##Scheithauer and Blum, 2004##), is often seen in patients treated with 5-FU and capecitabine, but was not observed at grades &gt;1 in the present study. This study was small, however, and larger studies would be required to allow definitive conclusions to be drawn regarding the propensity of UFT to cause this syndrome.</p> <p>UFT is a convenient alternative to infusional 5-FU, as it does not require the use of Hickman lines or pumps and therefore the complications associated with these modes of administration can be avoided (##REF##8691841##Puig-la Calle et al, 1996##). Studies have shown that patients prefer UFT to i.v. 5-FU regimens, with most patients citing the convenience of oral treatment as a reason for this preference (##REF##11818199##Borner et al, 2002##; ##REF##15842464##Rocha Lima and del Giglio, 2005##). However, patient preference is largely driven by tolerability, as shown by a recent study comparing capecitabine with the Nordic 5-FU/LV regimen (##REF##17011184##Pfeiffer et al, 2006##). In that study, i.v. 5-FU was preferred to oral capecitabine, primarily because capecitabine-treated patients had a higher incidence of adverse events, including diarrhoea and hand–foot syndrome, whereas the Nordic 5-FU regimen was well tolerated.</p> <p>One concern regarding the use of intensive up-front triple therapy is that the choice of second-line treatment may be limited when patients progress. This is not the case with SCOUT, as the tolerability of the alternating regimen meant that most patients (67% of those in the phase I/II study group) were able to receive further treatment, including repeated courses of SCOUT. Re-treatment with SCOUT, which occurred in 33% patients eligible for second-line therapy, resulted in further complete and partial responses. This is in agreement with a previous report that first-line FOLFOXIRI (5-FU, oxaliplatin and irinotecan) did not compromise the feasibility of second-line treatments (##REF##16766580##Masi et al, 2006##). In that study, 76% patients received second-line therapy and further responses were observed in 33% patients, similar to our findings. By virtue of their disease being chemosensitive, most patients (75%) who were suitable for second-line SCOUT went on to receive a third-line regimen, in contrast to only 25% of those who resumed alternate second-line chemotherapy. Again, this lends support to the good tolerability of SCOUT as well as to the concept that further alternate lines of chemotherapy are still possible after SCOUT.</p> <p>Other triple-drug regimens have been shown to result in excellent ORRs and survival. Objective response rates of 43–72% and OS of 21.5–28.4 months have been reported for FOLFOXIRI (##REF##15550581##Masi et al, 2004##; ##REF##16508637##Souglakos et al, 2006##; ##REF##17470860##Falcone et al, 2007##). Variations in response and survival outcomes are likely to be a result of differences in the regimens used, for example, the doses of irinotecan, oxaliplatin and 5-FU/LV were higher in the study by Falcone and colleagues. In addition, the characteristics of patients entered into the study also differed: patients in the study by Souglakos and colleagues were not required to be younger than 75 years and the proportion of patients with Eastern Cooperative Oncology Group performance status 2 was considerably higher (50% compared with 35% in the Hellenic Group study). The triple-drug combination of capecitabine, oxaliplatin and irinotecan (XELOXIRI) has also been investigated (##REF##17827459##Masi et al, 2007##; ##REF##17823385##Bajetta et al, 2007b##). Efficacy outcomes were good, with an ORR of 63% and median OS of 23.5 months in the study by Bajetta and colleages, and an ORR of 70% and median progression-free survival of 9.2 months in the study by Masi and colleagues. FOLFOXIRI and XELOXIRI, however, caused considerable haematological toxicity, neurotoxicity and diarrhoea. Grade 3/4 neutropaenia appears to be a particularly common problem with concurrent triple-drug therapy, although this was rare with the SCOUT regimen (grade 3 neutropaenia occurred in only 3% patients).</p> <p>Others have used 5-FU- and capecitabine-based alternating regimens with good results. Objective response rates of 46–54% and OS of 18–18.7 months have been observed in alternating 5-FU-based regimens, along with little neurotoxicity and myelotoxicity (##REF##16356303##Aparicio et al, 2005##; ##REF##16282707##Ferrari et al, 2005##; ##REF##16537184##Hebbar et al, 2006##). ##REF##16635282##Cassinello et al (2006)## reported a somewhat lower ORR of 37% and OS of 16.4 months for a regimen comprising oxaliplatin on day 1 with capecitabine on days 1–14 of a 21-day cycle, followed by irinotecan on day 1 plus capecitabine on days 1–14 of a second 21-day cycle. Nonetheless, this regimen was well tolerated, providing further support for the improved tolerability of alternating regimens.</p> <p>Considerable debate surrounds the optimal approach to treating patients with mCRC. Results from the CAIRO and FOCUS studies suggest that first-line monotherapy followed by second-line combination therapy is as effective as combination chemotherapy in the first line followed by monotherapy (##REF##17630036##Koopman et al, 2007##; ##REF##17630037##Seymour et al, 2007##). In contrast, OPTIMOX1 indicated that intensive first-line therapy with prolonged maintenance treatment and planned reintroduction of intensive therapy is a valid approach to treatment (##REF##16421419##Tournigand et al, 2006##). The OPTIMOX2 study has demonstrated, however, that a break in therapy between intensive treatments cannot be recommended (##UREF##0##Maindrault-Goebel et al, 2007##). The SCOUT approach avoids the need for discontinuing oxaliplatin, although reducing treatment intensity between full-dose courses may be attractive to some patients.</p> <p>Several limitations of this study need to be considered. This was a single-centre, non-randomised study, making direct comparisons with other studies difficult, and the patient numbers were small. In addition, this study did not include a targeted agent, such as cetuximab or bevacizumab, and therefore the question whether targeted agents might improve response and survival rates remains unanswered. However, it can be argued that the first priority in combination chemotherapy scheduling should be optimisation of the three well-known, conventional, active chemotherapy agents in mCRC. As stated by Saltz at ASCO in 2002, ‘we need all three drugs. We have conflicting data about how to best use them, but, clearly, we need to have them all available to our patients’. Evaluation of the role of the targeted agents combined with a well-tolerated and effective alternating regimen, like SCOUT, would be the next key step to improve outcomes further. Such a study is underway, in which the SCOUT regimen will be combined with cetuximab (E-SCOUT).</p> <p>In conclusion, UFT with LV plus alternating irinotecan and oxaliplatin is an effective, well-tolerated treatment approach for patients with mCRC. SCOUT results in high ORRs (63%, 95% CI: 49–80), respectable survival (median TTP and OS were 8.7 months (95% CI: 7.9–10.4) and 16.8 months (95% CI: 9.6–25.3), respectively), and the feasibility of second- and third-line treatments. SCOUT is convenient for both patients and hospital staff, as it avoids the need for tunnelled central lines and their associated complications, translating into saving out-patient time, in-patient admissions and clinical costs.</p>
<p>Tegafur–uracil (UFT) plus leucovorin® (LV, folinic acid) with alternating irinotecan and oxaliplatin were effective and well tolerated in patients with metastatic colorectal cancer (mCRC) in a phase I study. This study expanded the maximum tolerated dose group. Patients aged ⩾18 years had histologically confirmed, inoperable, previously untreated, measurable mCRC. Patients received irinotecan 180 mg m<sup>−2</sup> on day 1, oxaliplatin 100 mg m<sup>−2</sup> on day 15 and UFT 250 mg m<sup>−2</sup> plus LV 90 mg on days 1–21 every 28 days. The phase I/II study comprised 45 patients, 29 at the maximum tolerated dose (MTD). The response rate in 38 evaluable patients was 63% (95% confidence interval (CI): 49–80). Median time to progression and overall survival were 8.7 months (95% CI: 7.9–10.4) and 16.8 months (95% CI: 9.6–25.3), respectively. In the MTD group, one patient had grade 3 leucopaenia; one had grade 3 neutropaenia; three had grade 3 diarrhoea; and one had grade 3 neurotoxicity. No hand–foot syndrome grade &gt;1 was seen. In total, 67% of eligible patients received second-line therapy. UFT plus LV with alternating irinotecan and oxaliplatin is an efficacious first-line treatment for mCRC, with minimal neurotoxicity and hand–foot syndrome.</p>
<p>Patients with unresectable metastatic colorectal cancer (mCRC) have a poor prognosis in the absence of effective chemotherapy. The foundation of treatment for these patients is 5-fluorouracil (5-FU) with leucovorin® (LV), either alone or in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). Many patients with mCRC receive only first-line treatment (##TAB##0##Table 1##), with some refusing second-line therapy and preferring to preserve their quality of life, whereas others are not offered this option as they are considered unfit as a result of disease progression.</p> <p>Optimising first-line treatment is essential in mCRC. As exposure to three active agents, rather than second-line therapy itself, appears to predict improved survival (##REF##16361649##Grothey and Sargent, 2005##), ‘up-front’ administration of three effective drugs may be the most effective way to improve outcomes. Consequently, several groups have investigated the FOLFOXIRI combination (5-FU, oxaliplatin and irinotecan) in patients with mCRC (##REF##15550581##Masi et al, 2004##; ##REF##16508637##Souglakos et al, 2006##; ##REF##17470860##Falcone et al, 2007##). Results from phase III studies have been conflicting, however, with ##REF##17470860##Falcone et al (2007)## demonstrating better outcomes for patients treated with FOLFOXIRI compared with FOLFIRI, and ##REF##16508637##Souglakos et al (2006)## reporting no significant difference between the two regimens. Nonetheless, extremely promising overall survival (OS) rates were reported in these studies (22.6 months and 21.5 months, respectively), and a triple-drug approach holds great promise, provided the triplet regimen is tolerable.</p> <p>Toxicity is a significant problem with 5-FU-based regimens. Intravenous (i.v.) bolus 5-FU is associated with considerable myelosuppression (##REF##9817272##Meta-Analysis Group In Cancer, 1998##). Continuous infusion 5-FU, although less toxic, requires venous access using a tunnelled central line and portable infusion pumps, which are inconvenient for patients, while indwelling catheters can cause infection and thrombosis (##REF##8691841##Puig-la Calle et al, 1996##; ##REF##14512399##Verso and Agnelli, 2003##). The oral fluoropyrimidine tegafur–uracil (UFT) is a convenient and well tolerated alternative to i.v. 5-FU. In phase III studies, UFT with LV had equivalent efficacy compared to that of i.v. 5-FU/LV, but with significantly better tolerability (##REF##12202662##Carmichael et al, 2002##; ##REF##12202661##Douillard et al, 2002##). In both studies, UFT with LV was associated with significantly fewer haematological adverse events, including febrile neutropaenia, than bolus 5-FU/LV. In addition, patients in the UFT with LV group had a significantly lower incidence of stomatitis and other gastrointestinal events than 5-FU/LV. A number of small studies have shown that UFT can be combined with oxaliplatin (##REF##15505621##Feliu et al, 2004##; ##REF##16118508##Rosati et al, 2005##; ##REF##16404362##Bennouna et al, 2006##; ##REF##17245343##Bajetta et al, 2007a##) or irinotecan (##REF##15868381##Mendez et al, 2005##; ##REF##17637682##Delord et al, 2007##; ##REF##17245343##Bajetta et al, 2007a##), both combinations being effective and well tolerated in first-line mCRC.</p> <p>The present phase I/II study, SCOUT (study of CPT-11, oxaliplatin, UFT triple therapy), evaluated the efficacy and tolerability of UFT with LV plus alternating irinotecan and oxaliplatin in chemonaive patients with mCRC. We hypothesised that alternating oxaliplatin and irinotecan would allow patients to benefit from concurrent treatment with all three drugs as soon as they were diagnosed with metastatic disease, while allowing them to recover from adverse events associated with each drug before it was administered again. Results from the phase I study have been published in full (##REF##17213824##Sheikh et al, 2007##). Here we present results for the expanded group of patients treated at the maximum tolerated dose (MTD) and overall results from the phase I/II study.</p>
<p>We are very grateful to Bristol Myers Squibb and Merck KGaA (Darmstadt, Germany) for providing financial support towards data management and for the reduction of the cost of UFToral for use in this study. They provided no intellectual input into the writing of the protocol or the running of this study.</p>
<fig id="fig1"><label>Figure 1</label><caption><p>Kaplan–Meier curves for (<bold>A</bold>) overall survival (<italic>n</italic>=29) and (<bold>B</bold>) time to progression (<italic>n</italic>=27) for patients treated at the MTD, and (<bold>C</bold>) overall survival (<italic>n</italic>=45) and (<bold>D</bold>) time to progression (<italic>n</italic>=40) for all patients in the phase I/II study.</p></caption></fig>
<table-wrap id="tbl1"><label>Table 1</label><caption><title>Patients receiving second-line therapy in randomised clinical studies (adapted from ##REF##15051767##Grothey et al, 2004##)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">
<bold>First-line regimen</bold>
</th><th align="char" valign="top" char="." charoff="50">
<bold>Patients with second-line therapy (%)</bold>
</th><th align="char" valign="top" char="." charoff="50">
<bold>Patients administered three active drugs (%)</bold>
</th><th align="char" valign="top" char="." charoff="50">
<bold>Median overall survival (months)</bold>
</th><th align="left" valign="top" charoff="50">
<bold>Reference</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Irinotecan+bolus 5-FU/LV</td><td align="char" valign="top" char="." charoff="50">52</td><td align="char" valign="top" char="." charoff="50">5</td><td align="char" valign="top" char="." charoff="50">14.8</td><td align="left" valign="top" charoff="50">
##REF##11006366##Saltz et al (2000)##
</td></tr><tr><td align="left" valign="top" charoff="50">Irinotecan+bolus 5-FU/LV</td><td align="char" valign="top" char="." charoff="50">67</td><td align="char" valign="top" char="." charoff="50">24</td><td align="char" valign="top" char="." charoff="50">15.0</td><td align="left" valign="top" charoff="50">
##REF##14665611##Goldberg et al (2004)##
</td></tr><tr><td align="left" valign="top" charoff="50">Irinotecan+CIV 5-FU/LV</td><td align="char" valign="top" char="." charoff="50">39</td><td align="char" valign="top" char="." charoff="50">16</td><td align="char" valign="top" char="." charoff="50">17.4</td><td align="left" valign="top" charoff="50">
##REF##10744089##Douillard et al (2000)##
</td></tr><tr><td align="left" valign="top" charoff="50">Irinotecan+AIO</td><td align="char" valign="top" char="." charoff="50">56</td><td align="char" valign="top" char="." charoff="50">52</td><td align="char" valign="top" char="." charoff="50">20.1</td><td align="left" valign="top" charoff="50">
##REF##15939923##Köhne et al (2005)##
</td></tr><tr><td align="left" valign="top" charoff="50">Irinotecan+CIV 5-FU/LV</td><td align="char" valign="top" char="." charoff="50">81</td><td align="char" valign="top" char="." charoff="50">74</td><td align="char" valign="top" char="." charoff="50">21.5</td><td align="left" valign="top" charoff="50">
##REF##14657227##Tournigand et al (2004)##
</td></tr><tr><td align="left" valign="top" charoff="50">FOLFOX4</td><td align="char" valign="top" char="." charoff="50">58</td><td align="char" valign="top" char="." charoff="50">30</td><td align="char" valign="top" char="." charoff="50">16.2</td><td align="left" valign="top" charoff="50">
##REF##10944126##de Gramont et al (2000)##
</td></tr><tr><td align="left" valign="top" charoff="50">FOLFOX4</td><td align="char" valign="top" char="." charoff="50">75</td><td align="char" valign="top" char="." charoff="50">60</td><td align="char" valign="top" char="." charoff="50">19.5</td><td align="left" valign="top" charoff="50">
##REF##14665611##Goldberg et al (2004)##
</td></tr><tr><td align="left" valign="top" charoff="50">FOLFOX6</td><td align="char" valign="top" char="." charoff="50">62</td><td align="char" valign="top" char="." charoff="50">74</td><td align="char" valign="top" char="." charoff="50">20.6</td><td align="left" valign="top" charoff="50">
##REF##14657227##Tournigand et al (2004)##
</td></tr><tr><td align="left" valign="top" charoff="50">FOLFOX7</td><td align="char" valign="top" char="." charoff="50">73</td><td align="char" valign="top" char="." charoff="50">61</td><td align="char" valign="top" char="." charoff="50">21.2</td><td align="left" valign="top" charoff="50">
##REF##16421419##Tournigand et al (2006)##
</td></tr></tbody></table></table-wrap> <table-wrap id="tbl2"><label>Table 2</label><caption><title>Patient characteristics at baseline (patients treated at the MTD)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">
<bold>Characteristic</bold>
</th><th align="char" valign="top" char="(" charoff="50">
<bold>Value</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">No. of patients</td><td align="char" valign="top" char="(" charoff="50">29</td></tr><tr><td align="left" valign="top" charoff="50">Median age (range) (years)</td><td align="char" valign="top" char="(" charoff="50">57 (40–73)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Sex,</italic> n <italic>(%)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Male</td><td align="char" valign="top" char="(" charoff="50">25 (86)</td></tr><tr><td align="left" valign="top" charoff="50"> Female</td><td align="char" valign="top" char="(" charoff="50">4 (14)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Primary tumour site,</italic> n <italic>(%)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Colon</td><td align="char" valign="top" char="(" charoff="50">15 (52)</td></tr><tr><td align="left" valign="top" charoff="50"> Rectum</td><td align="char" valign="top" char="(" charoff="50">9 (31)</td></tr><tr><td align="left" valign="top" charoff="50"> Rectosigmoid</td><td align="char" valign="top" char="(" charoff="50">5 (17)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>WHO performance status,</italic> n <italic>(%)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> 0</td><td align="char" valign="top" char="(" charoff="50">15 (52)</td></tr><tr><td align="left" valign="top" charoff="50"> 1</td><td align="char" valign="top" char="(" charoff="50">11 (38)</td></tr><tr><td align="left" valign="top" charoff="50"> 2</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td></tr><tr><td align="left" valign="top" charoff="50"> Unknown</td><td align="char" valign="top" char="(" charoff="50">2 (7)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Prior surgical resection,</italic> n <italic>(%)</italic></td></tr><tr><td align="left" valign="top" charoff="50"> Radical</td><td align="char" valign="top" char="(" charoff="50">9 (31)</td></tr><tr><td align="left" valign="top" charoff="50"> Palliative</td><td align="char" valign="top" char="(" charoff="50">10 (34)</td></tr><tr><td align="left" valign="top" charoff="50"> Defunctioned only</td><td align="char" valign="top" char="(" charoff="50">2 (7)</td></tr><tr><td align="left" valign="top" charoff="50"> None</td><td align="char" valign="top" char="(" charoff="50">8 (28)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td colspan="2" align="left" valign="top" charoff="50">
<italic>No. of measurable lesions (%)</italic>
</td></tr><tr><td align="left" valign="top" charoff="50"> 1</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td></tr><tr><td align="left" valign="top" charoff="50"> 2</td><td align="char" valign="top" char="(" charoff="50">7 (24)</td></tr><tr><td align="left" valign="top" charoff="50"> ⩾3</td><td align="char" valign="top" char="(" charoff="50">21 (72)</td></tr></tbody></table></table-wrap> <table-wrap id="tbl3"><label>Table 3</label><caption><title>Anti-tumour efficacy of SCOUT</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">
<bold>Outcome, <italic>n</italic> (%)</bold>
</th><th align="char" valign="top" char="(" charoff="50">
<bold>Patients at all doses (<italic>n</italic>=45)</bold>
</th><th align="char" valign="top" char="(" charoff="50">
<bold>MTD patients (<italic>n</italic>=29)</bold>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Not assessable<xref ref-type="fn" rid="t3-fn1">a</xref></td><td align="char" valign="top" char="(" charoff="50">7</td><td align="char" valign="top" char="(" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">Evaluable patients</td><td align="char" valign="top" char="(" charoff="50">38</td><td align="char" valign="top" char="(" charoff="50">25</td></tr><tr><td align="left" valign="top" charoff="50">Complete response, <italic>n</italic> (%)<xref ref-type="fn" rid="t3-fn2">b</xref></td><td align="char" valign="top" char="(" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Partial response, <italic>n</italic> (%)<xref ref-type="fn" rid="t3-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">24 (63)</td><td align="char" valign="top" char="(" charoff="50">17 (68)</td></tr><tr><td align="left" valign="top" charoff="50">Stable disease, <italic>n</italic> (%)<xref ref-type="fn" rid="t3-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">10 (26)</td><td align="char" valign="top" char="(" charoff="50">8 (32)</td></tr><tr><td align="left" valign="top" charoff="50">Disease control rate (95% CI)<xref ref-type="fn" rid="t3-fn4">c</xref></td><td align="char" valign="top" char="(" charoff="50">89 (75–97)</td><td align="char" valign="top" char="(" charoff="50">100 (86–100)</td></tr><tr><td align="left" valign="top" charoff="50">Progressive disease, <italic>n</italic> (%)<xref ref-type="fn" rid="t3-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">4 (11)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Objective response rate (95% CI)</td><td align="char" valign="top" char="(" charoff="50">63 (46–78)</td><td align="char" valign="top" char="(" charoff="50">68 (46–85)</td></tr></tbody></table></table-wrap> <table-wrap id="tbl4"><label>Table 4</label><caption><title>Grade 3/4 adverse events per patient treated at the MTD (all cycles)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"> </th><th colspan="2" align="center" valign="top" char="(" charoff="50">
<bold>NCI-CTC grade, <italic>n</italic> (%) (<italic>N</italic>=29)</bold>
<hr/></th></tr><tr><th align="left" valign="top" charoff="50">
<bold>Event</bold>
</th><th align="char" valign="top" char="(" charoff="50">
<bold>3</bold>
</th><th align="center" valign="top" charoff="50">
<bold>4</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50">
<italic>Haematological</italic>
</td></tr><tr><td align="left" valign="top" charoff="50"> Anaemia</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Leucopaenia</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Neutropaenia</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Thrombocytopaenia</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="center" valign="top" charoff="50"> </td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">
<italic>Non-haematological</italic>
</td></tr><tr><td align="left" valign="top" charoff="50"> Alopecia</td><td align="char" valign="top" char="(" charoff="50">NA</td><td align="center" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50"> Anorexia</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Lethargy</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Nausea</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Vomiting</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Diarrhoea</td><td align="char" valign="top" char="(" charoff="50">3 (10)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Constipation</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> AST elevation</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Neuropathy</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Hand–foot syndrome</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Infection</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Abdominal pain</td><td align="char" valign="top" char="(" charoff="50">2 (7)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50"> Cardiac</td><td align="char" valign="top" char="(" charoff="50">0</td><td align="center" valign="top" charoff="50">1 (3)</td></tr></tbody></table></table-wrap> <table-wrap id="tbl5"><label>Table 5</label><caption><title>Second- and third-line therapy following SCOUT</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">
<bold>Regimen</bold>
</th><th align="char" valign="top" char="(" charoff="50">
<bold>No. of patients, <italic>n</italic> (%), at all doses (<italic>N</italic>=45)</bold>
</th><th align="char" valign="top" char="(" charoff="50">
<bold>No. of patients, <italic>n</italic> (%), at MTD (<italic>N</italic>=29)</bold>
</th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50">
<italic>Second-line therapy</italic>
</td></tr><tr><td align="left" valign="top" charoff="50"> Eligible for second-line therapy<xref ref-type="fn" rid="t5-fn2">a</xref></td><td align="char" valign="top" char="(" charoff="50">36</td><td align="char" valign="top" char="(" charoff="50">24</td></tr><tr><td align="left" valign="top" charoff="50">  Resumed SCOUT</td><td align="char" valign="top" char="(" charoff="50">12 (33)</td><td align="char" valign="top" char="(" charoff="50">9 (38)</td></tr><tr><td align="left" valign="top" charoff="50">  Mitomycin C/capecitabine</td><td align="char" valign="top" char="(" charoff="50">3 (8)</td><td align="char" valign="top" char="(" charoff="50">2 (8)</td></tr><tr><td align="left" valign="top" charoff="50">  Irinotecan/cetuximab</td><td align="char" valign="top" char="(" charoff="50">3 (8)</td><td align="char" valign="top" char="(" charoff="50">3 (13)</td></tr><tr><td align="left" valign="top" charoff="50">  Oxaliplatin/modified de Gramont</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="char" valign="top" char="(" charoff="50">1 (4)</td></tr><tr><td align="left" valign="top" charoff="50">  Oxaliplatin/capecitabine</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">  Capecitabine</td><td align="char" valign="top" char="(" charoff="50">1 (3)</td><td align="char" valign="top" char="(" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">  Phase I trial</td><td align="char" valign="top" char="(" charoff="50">3 (8)</td><td align="char" valign="top" char="(" charoff="50">3 (13)</td></tr><tr><td align="left" valign="top" charoff="50">  Unfit for further chemotherapy</td><td align="char" valign="top" char="(" charoff="50">12 (33)</td><td align="char" valign="top" char="(" charoff="50">6 (25)</td></tr><tr><td align="left" valign="top" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td><td align="char" valign="top" char="(" charoff="50"> </td></tr><tr><td align="left" valign="top" charoff="50"> </td><td colspan="2" align="center" valign="top" char="(" charoff="50">
<bold>No. of patients at all doses (<italic>N</italic>=45)</bold>
<hr/></td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">
<italic>Third-line therapy</italic>
</td></tr><tr><td align="left" valign="top" charoff="50"> Second-line SCOUT patients eligible for third-line therapy<xref ref-type="fn" rid="t5-fn3">b</xref></td><td colspan="2" align="center" valign="top" char="(" charoff="50">12</td></tr><tr><td align="left" valign="top" charoff="50">  Resumed SCOUT</td><td colspan="2" align="center" valign="top" char="(" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">  Mitomycin C/capecitabine</td><td colspan="2" align="center" valign="top" char="(" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">  Irinotecan/cetuximab</td><td colspan="2" align="center" valign="top" char="(" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">  Capecitabine</td><td colspan="2" align="center" valign="top" char="(" charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">  Phase I trial</td><td colspan="2" align="center" valign="top" char="(" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">  Unfit for further chemotherapy</td><td colspan="2" align="center" valign="top" char="(" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">  Not progressed on second-line therapy</td><td colspan="2" align="center" valign="top" char="(" charoff="50">1</td></tr></tbody></table></table-wrap>
<table-wrap-foot><fn id="t1-fn1"><p>AIO=Arbeitsgemeinschaft für Internistische Onkologie; CIV=continuous intravenous infusion; FOLFOX=5-FU/LV+oxaliplatin; 5-FU=5-fluorouracil; LV=Leucovorin®.</p></fn></table-wrap-foot> <table-wrap-foot><fn id="t2-fn1"><p>MTD=maximum tolerated dose; WHO=World Health Organization.</p></fn></table-wrap-foot> <table-wrap-foot><fn id="t3-fn1"><p>CI=confidence interval; MTD=maximum tolerated dose.</p></fn><fn id="t3-fn2"><label>a</label><p>Patients did not receive two treatment cycles and were thus not assessable for response.</p></fn><fn id="t3-fn3"><label>b</label><p>Based on the number of evaluable patients.</p></fn><fn id="t3-fn4"><label>c</label><p>Complete response+partial response+stable disease rates.</p></fn></table-wrap-foot> <table-wrap-foot><fn id="t4-fn1"><p>AST=aspartate aminotransferase; MTD=maximum tolerated dose; NA=not applicable; NCI-CTC=National Cancer Institute Common Toxicity Criteria.</p></fn></table-wrap-foot> <table-wrap-foot><fn id="t5-fn1"><p>MTD=maximum tolerated dose.</p></fn><fn id="t5-fn2"><label>a</label><p>Excludes patients who were not assessable for progression and those who had not progressed at the time of the analysis.</p></fn><fn id="t5-fn3"><label>b</label><p>Patients who received SCOUT as second-line therapy and were considered eligible for further treatment; excludes patients who had second-line treatments other than SCOUT.</p></fn></table-wrap-foot>
<graphic xlink:href="6604499f1"/>
[{"mixed-citation": ["Maindrault-Goebel F, Lledo G, Chibaydel B, Mineur L, Andre T, Mabro M, Artru P, Louvet C, de Gramont A ("], "year": ["2007"], "article-title": ["Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study"], "source": ["J Clin Oncol"], "volume": ["25"], "fpage": ["4013"]}]
Br J Cancer. 2008 Aug 19; 99(4):577-583